8-K: Monogram Technologies Reports Full Year 2024 Financial Results and Provides Business Update

Monogram Technologies announces its full year 2024 financial results, highlights progress on FDA submission, and discusses strategic collaborations.

Summary

• Monogram Technologies reported its financial and operational results for the fourth quarter and year ended December 31, 2024.
• The company completed all supplemental testing and submitted its formal response to the FDA's Additional Information Request (AIR) regarding its mBs Total Knee Arthroplasty (TKA) System.
• Monogram does not anticipate further requests for information from the FDA at this time.
• A strategic collaboration with Shalby Limited in India is progressing, with a robot shipped for clinical trial training and an Investigator Meeting held.
• The company closed an upsized and oversubscribed $13 million public offering.
• Management and related parties purchased $1 million of MGRM common stock in the open market.
• Monogram was named Orthopedic Joint Replacement Company of the Year 2024 by Medical Tech Outlook.
• Research and development expenses for 2024 were $8.8 million, a decrease of 17% compared to the prior year.
• Marketing and advertising expenses decreased by 30% to $2.1 million.
• General and administrative expenses increased by 9% to $4.4 million.
• The net loss for the year was $16.3 million, compared to a net loss of $13.7 million in the prior year.
• Cash and cash equivalents totaled $15.7 million as of December 31, 2024, compared to $13.6 million as of December 31, 2023.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to progress with the FDA submission and the successful capital raise, but tempered by the increased net loss and ongoing regulatory uncertainties.

Positives

• The company completed all supplemental testing and submitted its formal response to the FDA regarding the Additional Information Request (AIR) for its mBs TKA System.
• Monogram closed an upsized and oversubscribed $13 million public offering, strengthening its balance sheet.
• Management and related parties demonstrated confidence by purchasing $1 million of MGRM common stock.
• The company is progressing with its strategic collaboration with Shalby Limited in India, including shipping a robot for clinical trial training.
• Monogram was recognized as Orthopedic Joint Replacement Company of the Year 2024 by Medical Tech Outlook.
• Cash and cash equivalents increased to $15.7 million as of December 31, 2024.

Negatives

• The net loss for the year was $16.3 million, compared to a net loss of $13.7 million in the prior year.
• Marketing and advertising expenses decreased by 30% to $2.1 million.

Risks

• The company is awaiting a clearance decision from the FDA for its mBs TKA System, and there is no guarantee of a favorable outcome.
• Regulatory timelines for clinical trials in India can be variable.
• The company's success depends on its ability to commercialize the mBs TKA System and expand to new applications.

Future Outlook

The company is focused on obtaining FDA clearance for the mBs TKA System, pursuing clinical trials in India, and exploring domestic and international relationships to advance commercialization.

Management Comments

• 'The fourth quarter was marked by continued progress toward the commercialization of our mBs Total Knee Arthroplasty (TKA) System, and a strengthened balance sheet to provide the cash runway to meet near-term commercialization milestones,' said Ben Sexson, Chief Executive Officer of Monogram.
• Sexson also stated that the company is 'incredibly optimistic for 2025 and our mission to advance the standard of care in orthopedic medicine.'

Industry Context

Monogram Technologies operates in the orthopedic robotics market, which is characterized by increasing adoption of robotic-assisted surgery for joint replacements. Competitors include Stryker, Zimmer Biomet, and Smith & Nephew, all of whom are developing or marketing robotic systems for orthopedic procedures. Monogram's focus on AI-driven robotics and personalized implants positions it to potentially capture a share of this growing market.

Comparison to Industry Standards

• While specific financial comparisons are limited in the document, Monogram's R&D spending as a percentage of operating expenses is significant, reflecting its focus on innovation.
• Companies like Stryker and Zimmer Biomet, which are established players in the orthopedic market, have significantly higher revenue but also higher R&D budgets.
• Monogram's collaboration with Shalby Limited mirrors similar partnerships between medical device companies and international healthcare providers to expand market reach and conduct clinical trials, similar to Medtronic's partnerships in emerging markets.

Stakeholder Impact

• Shareholders: The $13 million public offering could dilute existing shareholders, but the strengthened balance sheet may be viewed positively.
• Employees: Continued R&D and product development efforts could provide job security and growth opportunities.
• Customers (Surgeons and Patients): Successful FDA clearance and commercialization of the mBs TKA System could lead to improved surgical outcomes and personalized implants.

Next Steps

• Obtain FDA clearance for the mBs TKA System.
• Obtain regulatory clearance to conduct clinical trials in India with Shalby Hospitals.
• Continue exploring domestic and international relationships.
• Continue R&D and product development to improve future competitiveness and expand to new applications.

Key Dates